发现了针对乳腺癌选择性向CDK2的新型纯素类似物:优化,合成,生物评估和对接研究
Mahesh Rupapara1,2, Nishith Teraiya3, Chetan Sangani4
1Department of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, 210008, People's Republic of China.
Molecular diversity
|May 29, 2025
概括
新的精氨酸衍生物通过抑制CDK2表现出强大的抗癌活性,为乳腺癌治疗提供了一个有前途的策略. 化合物5e和5f对三阴性乳腺癌细胞系表现出显著的有效性.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 循环素依赖激酶2 (CDK2) 是细胞循环的关键调节剂,也是乳腺癌的有希望的治疗标.
- 氨酸类似物已证明其作为抗癌剂的有效性,作为开发新疗法的支架.
- 三阴性乳腺癌 (TNBC) 仍然是一个具有挑战性的亚型,目标治疗选择有限.
研究的目的:
- 合成和描述基于纯素的新型化合物作为CDK2.2的潜在抑制剂.
- 评估这些化合物对乳腺癌细胞系的体外抗癌活性,包括TNBC.
- 评估最强效化合物的选择性和作用机制.
主要方法:
- 一系列的精氨酸衍生物 (5a-5j) 通过胺合和化合成.
- 使用光谱技术进行了化合物表征 (H NMR,C NMR,IR,MS,HMBC).
- 使用NCI-60试验,细胞毒性试验 (IC50确定) 和针对CDK2.2的分子对接研究来评估抗癌活性.
主要成果:
- 化合物5e和5f对MDA-MB-231细胞显著抑制了生长 (93%和91%,分别).
- 化合物5f对MDA-MB-231和MDA-MB-468 (TNBC) 细胞系表现出强烈的细胞毒性,其IC50值分别为0.19μM和0.72μM.
- 化合物5f对癌细胞的选择性高于非癌性Vero细胞 (选择性指数>120),与参考细胞相比,对CDK2抑制的亲和力更强 (IC50 = 0.47μM).
结论:
- 合成的精氨酸衍生物,特别是5f,由于其强大和选择性的CDK2抑制,代表了乳腺癌治疗的有希望的候选人.
- 使用缩HCl的高效合成方法为传统方法提供了经济高效的替代方案.
- 需要对5f化合物进行进一步的研究,以探索其在乳腺癌临床前模型中的治疗潜力.
相关概念视频
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Drug Discovery: Overview
12.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.2K
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K


